• Je něco špatně v tomto záznamu ?

Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma

MV. Mateos, S. Rigaudeau, S. Basu, I. Spicka, R. Schots, T. Wrobel, G. Cook, M. Beksac, KS. Gries, A. Kudva, B. Tromp, R. Van Rampelbergh, H. Pei, S. Wroblewski, R. Carson, M. Delioukina, D. White

. 2023 ; 29 (5) : 1172-1177. [pub] 20220906

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23010968

INTRODUCTION: Two phase 3 studies demonstrated superior efficacy of intravenous daratumumab (DARA IV) plus bortezomib/melphalan/prednisone (ALCYONE) or lenalidomide/dexamethasone (Rd; MAIA) versus standard-of-care regimens for transplant-ineligible newly diagnosed multiple myeloma. In these studies, patients could switch from DARA IV to subcutaneous daratumumab (DARA SC) while receiving daratumumab monotherapy in ALCYONE (as of Cycle 11) or daratumumab plus Rd in MAIA. The phase 3 COLUMBA study demonstrated noninferiority of DARA SC to DARA IV. DARA SC reduced administration time, allowing patients to spend less time in healthcare settings, a relevant practical consideration for patient care in the COVID-19 pandemic/settings of limited healthcare resources. METHODS: DARA SC 1800 mg was administered every 4 weeks, per approved dosing schedules. We evaluated safety and patient-reported experience (ALCYONE only) among patients who switched from DARA IV to DARA SC. RESULTS: Fifty-seven patients in ALCYONE and 135 in MAIA switched to DARA SC. Three (2.2%; MAIA) patients reported injection-site reactions, all of which were mild. No infusion-related reactions occurred with DARA SC. In ALCYONE, >80% of patients preferred DARA SC over DARA IV. Grade 3/4 treatment-emergent adverse events (TEAEs) occurred in 5.3% of patients in ALCYONE and 25.9% in MAIA; one (0.7%; MAIA) patient experienced a TEAE with an outcome of death. CONCLUSION: For transplant-ineligible newly diagnosed multiple myeloma, DARA SC (monotherapy/with Rd) was safe and preferred over DARA IV. ClinicalTrials.gov, NCT02195479/NCT02252172.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010968
003      
CZ-PrNML
005      
20230801132736.0
007      
ta
008      
230718s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/10781552221103551 $2 doi
035    __
$a (PubMed)36067063
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Mateos, Maria-Victoria $u University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain $1 https://orcid.org/0000000323901218
245    10
$a Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma / $c MV. Mateos, S. Rigaudeau, S. Basu, I. Spicka, R. Schots, T. Wrobel, G. Cook, M. Beksac, KS. Gries, A. Kudva, B. Tromp, R. Van Rampelbergh, H. Pei, S. Wroblewski, R. Carson, M. Delioukina, D. White
520    9_
$a INTRODUCTION: Two phase 3 studies demonstrated superior efficacy of intravenous daratumumab (DARA IV) plus bortezomib/melphalan/prednisone (ALCYONE) or lenalidomide/dexamethasone (Rd; MAIA) versus standard-of-care regimens for transplant-ineligible newly diagnosed multiple myeloma. In these studies, patients could switch from DARA IV to subcutaneous daratumumab (DARA SC) while receiving daratumumab monotherapy in ALCYONE (as of Cycle 11) or daratumumab plus Rd in MAIA. The phase 3 COLUMBA study demonstrated noninferiority of DARA SC to DARA IV. DARA SC reduced administration time, allowing patients to spend less time in healthcare settings, a relevant practical consideration for patient care in the COVID-19 pandemic/settings of limited healthcare resources. METHODS: DARA SC 1800 mg was administered every 4 weeks, per approved dosing schedules. We evaluated safety and patient-reported experience (ALCYONE only) among patients who switched from DARA IV to DARA SC. RESULTS: Fifty-seven patients in ALCYONE and 135 in MAIA switched to DARA SC. Three (2.2%; MAIA) patients reported injection-site reactions, all of which were mild. No infusion-related reactions occurred with DARA SC. In ALCYONE, >80% of patients preferred DARA SC over DARA IV. Grade 3/4 treatment-emergent adverse events (TEAEs) occurred in 5.3% of patients in ALCYONE and 25.9% in MAIA; one (0.7%; MAIA) patient experienced a TEAE with an outcome of death. CONCLUSION: For transplant-ineligible newly diagnosed multiple myeloma, DARA SC (monotherapy/with Rd) was safe and preferred over DARA IV. ClinicalTrials.gov, NCT02195479/NCT02252172.
650    _2
$a lidé $7 D006801
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $7 D000971
650    _2
$a bortezomib $x terapeutické užití $7 D000069286
650    12
$a COVID-19 $7 D000086382
650    12
$a mnohočetný myelom $x farmakoterapie $7 D009101
650    _2
$a pandemie $7 D058873
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
700    1_
$a Rigaudeau, Sophie $u Hôpital Andre Mignot, Service d'Hematologie et d'Oncologie, Le Chesnay, France
700    1_
$a Basu, Supratik $u Royal Wolverhampton Hospitals NHS Trust and University, Wolverhampton, UK
700    1_
$a Spicka, Ivan $u Clinical Department of Haematology, 1st Medical Department, Charles University in Prague, Prague, Czech Republic
700    1_
$a Schots, Rik $u UZ Brussel-VUB, Brussels, Belgium
700    1_
$a Wrobel, Tomasz $u Uniwersytet Medyczny we Wrocławiu, Wroclaw, Poland
700    1_
$a Cook, Gordon $u Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, UK
700    1_
$a Beksac, Meral $u Department of Hematology, Ankara University, Ankara, Turkey
700    1_
$a Gries, Katharine S $u Janssen Global Services, Raritan, NJ, USA
700    1_
$a Kudva, Anupa $u Janssen Research & Development, LLC, Raritan, NJ, USA
700    1_
$a Tromp, Brenda $u Janssen Research & Development, Leiden, The Netherlands
700    1_
$a Van Rampelbergh, Rian $u Janssen Research & Development, Beerse, Belgium
700    1_
$a Pei, Huiling $u Janssen Research & Development, LLC, Titusville, NJ, USA
700    1_
$a Wroblewski, Susan $u Janssen Research & Development, LLC, Spring House, PA, USA
700    1_
$a Carson, Robin $u Janssen Research & Development, LLC, Spring House, PA, USA
700    1_
$a Delioukina, Maria $u Janssen Research & Development, LLC, Spring House, PA, USA
700    1_
$a White, Darrell $u Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada
773    0_
$w MED00006367 $t Journal of oncology pharmacy practice $x 1477-092X $g Roč. 29, č. 5 (2023), s. 1172-1177
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36067063 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132732 $b ABA008
999    __
$a ok $b bmc $g 1963413 $s 1197233
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 29 $c 5 $d 1172-1177 $e 20220906 $i 1477-092X $m Journal of oncology pharmacy practice $n J Oncol Pharm Pract $x MED00006367
LZP    __
$a Pubmed-20230718

Najít záznam

Citační ukazatele

    Možnosti archivace